To determine the shortest duration of therapy needed to decrease the development of antimicrobial resistance and risk of antimicrobial toxicity.
Short course (5 day) therapy is superior to standard course (10-day) beta-lactam therapy (amoxicillin, amoxicillin/clavulanate, cefdinir).
Children aged 6 months to 6 years who have experienced early clinical improvement of pneumonia.
Participants must be willing to be randomized to usual care or the treatment group who will have 3 site visits (likely be in-home) where the study team will give instruction on medication and obtain vital signs and a physical assessment.
Benefits for patients and families include reducing adverse drug events experienced when taking antibiotics, potentially preserving the patients’ microbiome, and helping reduce the rate of antibiotic resistance.
Jason Newland, MD, MEd, Professor of Pediatrics, Infectious Diseases, and Stephanie A. Fritz, MD, MSCI, Associate Professor of Pediatrics, Infectious Disease Washington University School of Medicine.